ClinicalTrials.gg
Active, not recruitingNCT07183189Updated Sep 25, 2026

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

A Phase 3 interventional study of SHR-A2009 ; Aumolertinib and Aumolertinib in Non-small Cell Lung Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
582
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 18 under way, 7 of them phase 3. aumolertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 29
582 · median 150
Started
2025
with 1 other
Phase 3
11 of 29
4 open now
Primary completion
2032-11
later than 17 of 17 live
Registered
27th of 29
by date
Lead sponsor
2 of 29
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Among the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 2 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About aumolertinib

aumolertinib: first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aumolertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years (inclusive) at the time of signing , regardless of gender.
  2. Subjects with or cytologically confirmed locally advanced, , or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.
  3. No prior systemic therapy for locally advanced, metastatic, or recurrent non-small cell lung cancer.
  4. At least one measurable tumor lesion according to v1.1.
  5. performance status of 0 or 1.
  6. Expected survival time ≥12 weeks.
  7. Adequate bone marrow and organ function.
  8. Subjects must provide informed consent prior to the trial and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed combined small cell lung cancer (SCLC), neuroendocrine carcinoma, sarcomatoid carcinoma, or carcinosarcoma components.
  2. Subjects with a history of , brainstem , or spinal cord metastasis.
  3. Subjects with uncontrolled tumor-related pain, as determined by the investigator.
  4. Clinically uncontrolled third-space fluid accumulation, as determined by the investigator.
  5. Insufficient time interval between prior antitumor therapy and the first dose administration.
  6. Major organ surgery or significant trauma within 4 weeks prior to the first dose of the study drug.
  7. History of other within ≤5 years prior to the first dose.
  8. Subjects with a history of interstitial lung disease, or imaging at screening suggestive of suspected interstitial lung disease; or other moderate to severe pulmonary diseases severely affecting lung function.
  9. Severe cardiovascular or cerebrovascular diseases.
  10. Any severe or uncontrolled ocular lesions that, in the physician's judgment, may increase the patient's safety risk.
  11. nausea, vomiting, chronic gastrointestinal diseases, etc.
  12. Severe infections within 4 weeks prior to the first dose.
  13. Subjects with arterial/venous thromboembolic events within 6 months prior to the first dose of the study drug.
  14. Active tuberculosis infection.
  15. History of immunodeficiency, including positive test.
  16. Active or .
  17. Prior hematopoietic stem cell transplantation or organ transplantation.
  18. History of severe allergic reactions to aumolertinib or other monoclonal antibodies, or to any component of SHR-A2009.
  19. Known history of alcohol or drug dependence or drug abuse.
  20. Psychiatric disorders or poor compliance.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
582 participants (actual)

Study arms

  • Experimental
    investigational treatment group:SHR-A2009 combined with Aumolertinib

    Drug: SHR-A2009 ; Aumolertinib

  • Active comparator
    control group :Aumolertinib

    Drug: Aumolertinib

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by BICR according to RECIST v1.1

    Time frame: Up to approximately 38 months

Secondary outcomes

  1. overall survival (OS)

    Time frame: Up to approximately 60 months

  2. Progression Free Survival(PFS by investigator)

    Time frame: Up to approximately 38months

  3. Duration of response(DoR,by BICR and investigator )

    Time frame: Up to approximately 38 months

  4. Disease control rate(DCR,by BICR and investigator)

    Time frame: Up to approximately 38 months

  5. Incidence of AEs

    Time frame: from Day1 to 40 days after last dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Nov 2032, 85 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 85 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Sep 19, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Nov 2032
CompletionEst.
Dec 2032
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Enrollment
576 (estimated)→582 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    Enrollment 576 (estimated)→582 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07183189
Responsible party
Sponsor
First posted
Sep 19, 2025
Start date
Oct 30, 2025
Primary completion
Nov 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ruzaltatug rezetecan · Aumolertinib

Start the discussion